We are driven by a vision to end cancer mortality. Our company was founded on this vision in 2007. Tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. Our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. At the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. In other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ healthy tissue intact while the tumor is destroyed. We believe Tocagen’s approach to fighting cancer using RRVs is an important scientific advancement over prior gene therapy approaches, as well as a potential complement to existing therapies. We believe our innovations may fulfill the promise of gene therapy as a safe and effective treatment for cancer. Ultimately, Tocagen exists for the patients, powered by a mission to revolutionize cancer treatment. With the right therapeutic approach, our hope is that even the most aggressive forms of cancer can be safely and effectively controlled, and each day we strive to turn that bold vision into reality.
View Top Employees from Tocagen Inc.Website | http://www.tocagen.com |
Ticker | TOCA |
Revenue | $18 million |
Funding | $83.4 million |
Employees | 54 (18 on RocketReach) |
Founded | 2007 |
Address | 4242 Campus Point Ct, Ste 500, San Diego, California 92121, US |
Phone | (858) 412-8400 |
Technologies |
JavaScript,
HTML,
GoDaddy DNS
+7 more
(view full list)
|
Industry | Biotechnology, Education, Organizations, Biopharma, Drug Discovery, Gene Transfer Technology, Pharmaceuticals, Other Pharmaceuticals and Biotechnology, Research, Health Care, Science and Engineering, Genetics, Therapeutics |
Web Rank | 3 Million |
Keywords | Tocagen, Glioblastoma Statistics, Statistics On High Grade Gliomas, Fda Approved Drugs For Glioblastoma, Ucsf Nursing Phd Linkedin |
Competitors | Abeona Therapeutics, Aduro Biotech Europe, Arcus Biosciences, Kite Pharma, Precision Biologics |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 5417 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Tocagen Inc. employee's phone or email?
The Tocagen Inc. annual revenue was $18 million in 2023.
Doug Jolly is the Founder, Executive Vice President, Research and Pharmaceutical Development of Tocagen Inc..
18 people are employed at Tocagen Inc..
Tocagen Inc. is based in San Diego, California.
The NAICS codes for Tocagen Inc. are [54, 541, 32, 32541, 5417, 3254, 325].
The SIC codes for Tocagen Inc. are [87, 873].